Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts – The MAK Daily

The stock of Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) registered an increase of 13.43% in short interest. BLRXs total short interest was 2.28M shares in September as published by FINRA. Its up 13.43% from 2.01M shares, reported previously. With 811,500 shares average volume, it will take short sellers 3 days to cover their BLRXs short positions.

The stock decreased 1.06% or $0.03 during the last trading session, reaching $2.81. About 15,380 shares traded. BioLineRx Ltd. (NASDAQ:BLRX) has declined 70.47% since September 20, 2018 and is downtrending. It has underperformed by 70.47% the S&P500.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company has market cap of $28.73 million. The Companys development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. It currently has negative earnings. The companys other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

More notable recent BioLineRx Ltd. (NASDAQ:BLRX) news were published by: Nasdaq.com which released: BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher Nasdaq on October 05, 2018, also Seekingalpha.com with their article: BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2019 Results Earnings Call Transcript Seeking Alpha published on May 14, 2019, Seekingalpha.com published: BioLineRx down 21% on mid-stage data for BL-8040 in pancreatic cancer Seeking Alpha on October 19, 2018. More interesting news about BioLineRx Ltd. (NASDAQ:BLRX) were released by: Nasdaq.com and their article: 3 Cheap Biotech Stocks The Big Boys Are Buying Nasdaq published on May 12, 2017 as well as Finance.Yahoo.coms news article titled: BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update Yahoo Finance with publication date: August 06, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Follow this link:

Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts - The MAK Daily